...
首页> 外文期刊>Journal of the Saudi Heart Association >Congestive heart failure disease management program: 1-Year population experience from a tertiary center heart failure registry in Saudi Arabia
【24h】

Congestive heart failure disease management program: 1-Year population experience from a tertiary center heart failure registry in Saudi Arabia

机译:充血性心力衰竭疾病管理计划:从沙特阿拉伯的三级中心心力衰竭登记处获得的1年人口经验

获取原文

摘要

Aims We aimed to evaluate congestive heart failure (CHF) multidisciplinary disease management program (DMProg) impact on mortality, readmission rates, length of stay (LOS), and gender health characteristics. Methods and results This was a quasi-observational, pre- and post-trial with a parallel nonequivalent group. We enrolled 174 inpatients having CHF with reduced ejection fraction and New York Heart Association (NYHA) Class II–IV, and a total of 197 hospital admissions. A comparative follow-up was performed from 15 December 2014 to 15 December 2015. Among 197 consecutive hospital admissions, 76 (39%) were included in the preintervention or usual care group and 121 (61%) were assigned to the postintervention group. After 1 year, in comparison with the preintervention group, the postintervention group had shorter average LOS in days (7.6 days vs. 11.1 days, p 0.002), lower 1-year readmission rate (36% vs. 57%, p 0.003), and lower in-house mortality (1.6% vs. 7.8%, p = 0.03), but similar baseline mortality scores (38.2 vs. 38.6, p = 0.7), 30-day and 90-day readmission rates (15% vs. 18.3%, p = 0.62 and 27.6% vs. 30%, p = 0.65), and 30-day readmission risk score (24.9% vs. 26.2%, p = 0.09). By regression analysis, the DMProg intervention was an independent factor for 1-year readmission reduction ( p = 0.001). Kaplan–Meier survival analysis favored the postintervention group (log-rank, p 0.001). Conclusion DMProg significantly decreased 1-year readmission rates, LOS, and in-house mortality.
机译:目的我们旨在评估充血性心力衰竭(CHF)多学科疾病管理计划(DMProg)对死亡率,再入院率,住院时间(LOS)和性别健康特征的影响。方法和结果这是一个准观察性试验,在审判前和审判后有一个平行的非对等组。我们纳入了174例射血分数降低的CHF住院患者和纽约心脏协会(NYHA)II-IV级患者,共入院197例。从2014年12月15日至2015年12月15日进行了比较性随访。在197例连续入院患者中,干预前或常规护理组中包括76例(39%),干预后组中包括121例(61%)。 1年后,与干预前组相比,干预后组的平均LOS天数较短(7.6天vs. 11.1天,p <0.002),较低的1年再入院率(36%vs. 57%,p <0.003) )和更低的内部死亡率(1.6%vs. 7.8%,p = 0.03),但基线死亡率评分(38.2 vs. 38.6,p = 0.7),30天和90天再入院率相似(15%vs 18.3%,p = 0.62和27.6%vs. 30%,p = 0.65),以及30天的再入院风险评分(24.9%vs. 26.2%,p = 0.09)。通过回归分析,DMProg干预是1年再入院减少的独立因素(p = 0.001)。 Kaplan–Meier生存分析偏爱干预后组(log-rank,p <0.001)。结论DMProg可显着降低1年再入院率,LOS和内部死亡率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号